NEW YORK (GenomeWeb) – Curetis announced today that it has signed collaboration and commercialization deals with BGI Group subsidiary MGI to combine their technologies for next-generation sequencing-based infectious disease testing.

The firms said they plan to combine Curetis' Unyvero Lysator-based sample preparation technology and MGI's NGS to create a fully automated workflow that allows for the processing of any type of native clinical sample, with the subsequent NGS-based detection of microbial pathogens and genetic markers for antibiotic resistance. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.